triazolam has been researched along with Psychotic Disorders in 1 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
Psychotic Disorders: Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 39-year-old man with schizoaffective disorder experienced somnambulism only when taking a combination of lithium carbonate, chlorpromazine, triazolam, and benztropine." | 1.27 | Medication-induced somnambulism in a patient with schizoaffective disorder. ( Darko, D; Gillin, JC; Glassman, JN, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Glassman, JN | 1 |
| Darko, D | 1 |
| Gillin, JC | 1 |
1 other study available for triazolam and Psychotic Disorders
| Article | Year |
|---|---|
Medication-induced somnambulism in a patient with schizoaffective disorder.
Topics: Adult; Benztropine; Chlorpromazine; Humans; Lithium; Lithium Carbonate; Male; Psychotic Disorders; P | 1986 |